Plassonmore shares jumped sharply after the Israeli home ultrasound company announced a strategic distribution agreement in the United States with Ouma Health, a telemedicine company focused on pregnancy and childbirth. Ahead of the Nasdaq opening, the stock implied a company valuation of about $22 million.
Plassonmore develops a device for home ultrasound scans, mainly for high-risk pregnant women who want to monitor the fetus frequently without going to a clinic or hospital. The company was founded by Dr. Elazar Sonnenschein, who also founded the listed company Medigus. In Israel, it has an agreement with Clalit Health Services, and it received U.S. Food and Drug Administration approval to market the product in the U.S. at the end of 2025.
Under the new deal, Ouma will incorporate Plassonmore's products into its pregnancy-monitoring telemedicine offering. Ouma sells these services directly to patients and also through medical clinics or insurance plans. The financial terms of the agreement were not disclosed, and the deal remains confidential on those terms.
Plassonmore reports semiannual financial statements, so it has not yet published data showing adoption of the technology in the U.S. To date in 2025, it recorded revenue of 9.4 million shekels and a loss of 15 million shekels. Since its 2021 Tel Aviv listing, the stock has fallen about 91%, and since its Nasdaq debut it had lost 42% by this morning. The company previously had a strategic distribution deal with GE Healthcare, but that arrangement ended after clinical development slowed once the COVID-19 pandemic eased and GE raised concerns about the pace of progress. GE is no longer a shareholder. Plassonmore still reached FDA approval on its own and then listed on Nasdaq in early 2026.
